Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

André Heeres, Hu Xu (First author), Denise MS van Marion (First author), Femke Hoogstra-Berends, Deli Zhang, Jean-Paul Seerden, Lizette Loen, Herman Steen, Robert H Henning, Bianca J J M Brundel

Research output: Contribution to journalArticleAcademicpeer-review

46 Downloads (Pure)

Abstract

Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.

Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.
Original languageEnglish
Pages (from-to) 345—364
JournalDrug design, development and therapy
Volume13
Publication statusPublished - 18 Jan 2019

Keywords

  • atrial fibrillation
  • heat shock protein
  • drosophila
  • proteostasis
  • geranylger­anylacetone

Fingerprint Dive into the research topics of 'Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation'. Together they form a unique fingerprint.

  • Cite this

    Heeres, A., Xu , H., van Marion, D. MS., Hoogstra-Berends, F., Zhang, D., Seerden, J-P., Loen, L., Steen, H., Henning, R. H., & Brundel, B. J. J. M. (2019). Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. Drug design, development and therapy, 13, 345—364 .